SCYNEXIS
Manufacturing · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Evertrust Plz Fl 13, Jersey City, New ...Phone Number
(201) 884-5485Website
www.scynexis.comRevenue
$19.2 MillionStock Symbol
SCYXIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About SCYNEXIS
SCYNEXIS Inc is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant.Explore more
SCYNEXIS Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SCYNEXIS your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on SCYNEXIS recently announced quarterly report
Click to see if SCYNEXIS had a recent Job posting/layoffs
Check out if SCYNEXIS is spiking on competitors!
Check if SCYNEXIS has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once SCYNEXIS has new funding data
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
SCYNEXIS, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when SCYNEXIS launches new products
Congratulate Masked Content for being promoted to Masked Content at SCYNEXIS
Recommended Actions
Find VP level buyers at SCYNEXIS
Find 3 more new buyers
Compare Similar Companies to SCYNEXIS
Compare insights from companies similar to SCYNEXIS, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
SCYNEXIS is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
SCYNEXIS is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about SCYNEXIS.
SCYNEXIS financials insights
Gather financial insights about SCYNEXIS, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Stock Offering
$62M
2016
Debt
$15M
2020
Multiple Rounds
$115M
2021
Debt
$60M
SCYNEXIS Tech Stack
A closer look at the technologies used by SCYNEXIS
Most Recent Scoops
Person-Based
Governance
Person-Based
Pharmaceuticals, Finance, Financing & Debt
Person-Based
Proof of Concept (POC)
Person-Based
Acquisitions
Person-Based
Acquisitions
SCYNEXIS News & Media
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Dose-optimization data from the Phase 1 study expected Q3 2026 to support Phase 2 proof-of-concept initiation in ADPKD in Q4 2026 Dose-optimization data from the Phase 1 study expected Q3 2026 to support Phase 2 proof-of-concept initiation in ADPKD in Q4 2026SCYNEXIS Announces One-for-Eight Reverse Stock Split
SCYNEXIS’s Common Stock to Begin Trading on Post-Split Adjusted Basis on June 1, 2026 SCYNEXIS’s Common Stock to Begin Trading on Post-Split Adjusted Basis on June 1, 2026SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
JERSEY CITY, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today reported financial results for the first quarter ended March 31, 2026.SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
JERSEY CITY, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) (“SCYNEXIS” or the “Company”), a biotechnology company focused on developing innovative new therapies to address severe rare diseases including SCY-770 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), today announced that on April 30, 2026, the Compensation Committee of the Company’s Board of Directors approved inducement equity awards for a new Vice President in connection with the commencement of employm
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding SCYNEXIS
Sign Up For FreeTo access detailed company insights
SCYNEXIS Inc is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant.... Read More
